Background -Current guidelines on the management of asthma advocate the use of anti-inflammatory treatment in all but mild disease. They define disease control in terms of clinical criteria such as lung function and symptoms. However, the relationship between the clinical control of the disease and inflammation of the airways is not clear. A cross sectional study was therefore undertaken to investigate the relationship between airways inflammation and measures of clinical control and bronchial hyperresponsiveness in asthmatic patients treated with inhaled steroids. Methods -Twenty six atopic adults (19-45 years) with mild to moderate asthma (baseline forced expiratory volume in one second (FEVy) . 50% predicted, concentration of histamine causing a 20% fall in FEV1 (PC20) 0-02-7-6 mglml) on regular treatment with inhaled steroids entered the study. Diary card recordings during the two weeks before a methacholine challenge test and bronchoscopic examination were used to determine peak flow variability, symptom scores, and use of P2 agonists. Biopsy specimens were taken by fibreoptic bronchoscopy from the carina of the right lower and middle lobes, and from the main carina. Immunohistochemical staining was performed on cryostat sections with monoclonal antibodies against: eosinophil cationic protein (EG1, EG2), mast cell tryptase (AA1), CD45, CD22, CD3, CD4, CD8, CD25, and CD45RO. The number of positively stained cells in the lamina propria was counted twice by using an interactive display system. Results -There were no differences in cell numbers between the three sites from which biopsy specimens were taken. The PC20 for methacholine was inversely related to the average number of total leucocytes, EG1 +, and EG2 + cells, mast cells, CD8 +, and CD45RO + cells in the lamina propria. These relationships were similar for each of the biopsy sites. Symptom scores, P2 agonist usage, FEV1, and peak flow variability were not related to any of the cell counts.
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hyperAsthma is a chronic inflammatory disorder of the airways with a characteristic infiltrate of mast cells, lymphocytes, and eosinophils in the bronchial epithelium and lamina propria.'2 The symptoms ofwheezing, chest tightness, difficult breathing, and coughing develop after exposure to bronchoconstrictor stimuli and are associated with variable airways obstruction3 which can be provoked in the laboratory, thereby demonstrating airway hyperresponsiveness.3 The disease state can therefore be assessed at different levels: the severity of symptoms, the level of obstruction and degree of airway hyperresponsiveness, and the extent of airway disease.
To date there is no "gold standard" parameter that ultimately reflects asthma severity towards which therapeutic interventions should be aimed.45 The present international consensus on the diagnosis and treatment of asthma is based on the working hypothesis that it is desirable to reverse or prevent airways inflammation.2" However, at present the treatment level is solely guided by clinical indices such as symptoms and lung function34 and the current therapeutic approach is based on the assumption that there is a relationship between the clinical indices of asthma severity and airways inflammation.
When using the scoring system of Aas to assess symptoms over a one year period, it has been shown that the severity of the symptoms is related to the number and activity of eosinophils in the airways epithelium and in the bronchoalveolar lavage (BAL) fluid of patients with atopic asthma.8 The forced expiratory volume in one second (FEVy), expressed as a percentage of the predicted value,9-10 and airway hyperresponsiveness to inhaled methacholine9 12 are positively related to the number and activity ofeosinophils and activated CD4 + T cells in BAL fluid from subjects with atopic asthma. Furthermore, the provocative concentration of methacholine causing a 20% fall in FEV1 (PC20) has also been shown to be related to the number of activated eosinophils in bronchial biopsy specimens.7'314 Hence, there is evidence that some of the clinical indices of asthma are associated with airways inflammation, at least in patients not on treatment with anti-inflammatory medications.
In order to adjust treatment in patients using anti-inflammatory drugs, the international guidelines rely on the following clinical characteristics: symptom severity, 12 agonist usage, peak flow variability, and spirometric parameters.3415 To date it has not been systematically investigated which of these indices is most closely related to the level of airways inflammation in asthmatics using inhaled corticosteroids. In addition, it is still unclear whether measures of airways responsiveness can provide complementary information to symptoms and lung function on the disease state of the airways in these patients.
In the present study we have investigated whether clinical asthma severity, expressed according to present guidelines, is related to inflammatory activity in the airways of patients already using regular inhaled steroids. was within the normal range (>80% predicted). The PC20 for histamine at the start of the study was 0-02-7-3 mg/ml (geometric mean 0-42 mg/ ml). Symptoms were additionally controlled by on demand usage of short acting 12 agonists that were withheld for at least eight hours before each challenge test. All subjects gave their informed consent and the study was approved by the local ethical committee.
STUDY DESIGN
The study was of a cross sectional design. At entry to the study the subjects were equipped with diary cards and a mini-Wright peak flow meter and were asked to record symptoms, peak flow rates (PEF), and bronchodilator usage on the diary cards during the two weeks before the methacholine challenge test. Fibreoptic bronchoscopy was carried out 3-6 days later.
DIARY CARDS
The symptom score parameter was calculated from the diary card scores for night time asthma, morning tightness ofthe chest, daytime asthma, and daytime cough.'7 Each item could range from 0 to 4 on each day. The highest score for each day among these four items was then added up over a period of 14 days.
Bronchodilator usage was recorded as the total number of puffs of salbutamol or ipratropium bromide during 14 days registered on the diary cards and was expressed per week. ' (range 0-51). The mean FEV, before the methacholine challenge was 90% of predicted (range 51-120% predicted). The mean PEF variability was 10-3% (range 2-1-27-1) and the geometric mean methacholine PC20 was 0-73 mg/ml (range 0-02-18-2 mg/ml). The mean (SD) numbers of (sub) populations of leucocytes per area (cells/mm2) in the lamina propria of biopsy specimens at the subsegmental level of the right lower lobe, the segmental level of the middle lobe, and the central level of the main carina are shown in table 2. No significant differences in cell numbers were seen between the three sites. CD25 + cells were only found in one subject and were therefore excluded from statistical analysis. The relationships between the clinical indices of asthma severity and the average cell counts at the three sites are shown in table 3. 
Discussion
This study shows that infiltration of inflammatory cells in the lamina propria of the airways seems to persist despite regular treatment with inhaled steroids in asthmatic outpatients. In addition, it appears that, among the clinical indices of asthma severity, the degree of airway hyperresponsiveness to methacholine is most closely related to the number of leucocytes, (activated) eosinophils, mast cells, CD8 +, and CD45RO + lymphocytes in bronchial biopsy specimens from atopic asthmatic subjects who are receiving treatment with inhaled steroids. This inverse relationship is a consistent one and is observed at the (sub) segmental level in the right lower lobe, the middle lobe, and the main carina. It is remarkable that the most commonly used clinical indices such as symptom severity, P2 agonist usage, peak flow variability, and FEV1 are not significantly correlated with inflammatory cell counts in the lamina propria of the airways. These findings may have implications for the adjustment of anti-inflammatory treatment in asthma.
There have been a number of conflicting reports on the relationship between mast cell or eosinophil number in bronchial biopsy specimens and the clinical indices in atopic asthma. It has been reported that symptom severity over a one year period is related to the number and activity of eosinophils in the airway epithelium and in the BAL fluid in patients not on treatment with anti-inflammatory medications.8 14 However, in our group of atopic asthmatic subjects using inhaled corticosteroids we group.bmj.com on January 28, 2018 -Published by http://thorax.bmj.com/ Downloaded from subjects who were not using inhaled corticosteroids.22 Thus, a relationship between airways hyperresponsiveness and histopathology may only be revealed by using a sufficiently large group of atopic asthmatics characterised by a wide range of airways hyperresponsiveness as in the present study.
The absence of a relationship between clinical indices of asthma severity and histopathology of the airways does not seem to be caused by patient selection, study design, statistical power, or the processing and analysis of bronchial biopsy specimens for the following reasons. Firstly, in order to ensure that time related variability in the measurements did not obscure potential associations, the bronchoscopy was carried out within six days of the FEV, and PC20 measurements and last diary card registrations. Secondly, the patients in this study were carefully selected to be nonsmokers, having atopic asthma of mild to moderate severity with a wide range in FEV, between 51% and 120% of the predicted value. Thirdly, with the present number of subjects a correlation coefficient of .0-40 or < -040 yields a p value <0 05. Therefore, it seems unlikely that the absence of a significant correlation of modest strength can be explained by a problem with the power of the study. It can be argued that the use of inhaled steroids by these patients might have masked a potential relationship between clinical indices and cell counts.24 Due to the method ofpatient selection we cannot exclude such a possibility, because this study was designed to assess which parameter among the clinical indices best reflects the degree of airways inflammation in patients already using anti-inflammatory treatment.
The range and mean numbers of infiltrating inflammatory cells in the bronchial biopsy specimens in our study were How can the present results be interpreted? The association between eosinophils and mast cells in the lamina propria and methacholine responsiveness fits in with their role in the development of airways hyperresponsiveness.27
This includes secretion of a variety of inflammatory mediators capable of inducing epithelial desquamation, plasma extravasation, and hypersecretion, thereby increasing the thickness ofthe airway wall. 228 The complexity of the pathophysiology of asthma is well illustrated by our present findings. In four subjects who reported symptoms we were unable to detect an infiltrate of eosinophils in the lamina propria. In contrast, some other subjects had clear evidence of airway inflammation in spite of the absence of symptoms and with lung function parameters within the normal range.
The latter finding extends observations in acute severe asthma indicative of a dissociation between clinical recovery and bronchial hyperresponsiveness29 and is in keeping with a persistent increase in airways responsiveness in subjects who are clinically considered to be in remission of asthma.303' Our findings seem to implicate that the presence of an inflammatory infiltrate does not in itself lead to symptoms of asthma or airways obstruction, but might point to long term disease activity.
According to the current international recommendations for the treatment of asthma3 4 32 the level of anti-inflammatory treatment is chosen to minimise symptoms, optimise lung function, and to prevent exacerbations. The dosage of regular treatment should be kept to the minimum level that fulfils these objectives. The question is whether this approach leads to the optimal long term outcome of asthma. A number of studies have shown that treatment with inhaled steroids up to four months is very effective, particularly in reducing the number of mast cells and eosinophils in the airway wall which is often parallelled with improvements in symptoms, lung function, and airways hyperresponsiveness to methacholine.23243334 Longer term studies on the effect of inhaled steroids on the histopathology of the airways have not yet been reported. However, the observation that airways hyperresponsiveness continues to improve even after six months of treatment, when no further increase in FEV1 occurs, [35] [36] [37] suggests that it may take relatively longer to resolve the airway histopathology.
It can be argued that maintenance of an inflammatory state of the airways may result in anatomical changes and functional disorders.'538 This might be reflected by abnormal PC20 levels since two recent population based prospective studies have shown that airways hyperresponsiveness is a significant predictor of subsequent accelerated decline in pulmonary function. 3940 We therefore postulate that, in addition to the current guidelines, the treatment of asthma should also be directed towards reducing airways hyperresponsiveness. This might benefit the long term goal of asthma management as formulated in the international guidelines -that is, the prevention of the development of irreversible airways obstruction. 15 3641 Clearly, such a treatment regimen needs to be tested in long term prospective studies.
